Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant (BMTSLPRCT)
Randomized Clinical Study Comparing the Effectiveness of the Stanford Letter to the Traditional Advance Directive in Bone Marrow Transplant Recipients
The purpose of the proposed research study is to evaluate whether bone marrow transplant patients prefer the Stanford letter advance care planning tool to the standard Advance directive.
Completion of advance care planning prior to BMT is very important, but not often done. The investigators believe that the Stanford Letter will be preferred by patients and will allow them to feel more comfortable and share more of their wishes with family members and the medical team.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
PRIMARY OBJECTIVES I. To compare advance care planning (ACP) completion rate amongst bone marrow transplant (BMT) recipients receiving the Stanford Letter versus the traditional advance directive (AD) through a prospective, pilot randomized controlled trial (RCT).
SECONDARY OBJECTIVES:
I. To evaluate differences in patient preference for choice to prolong life following completion of the ACP tool in each group.
II. To assess uncertainty with decision making regarding end of life care following completion of the ACP tool in each group.
III. To explore patient understanding of and satisfaction with the ACP tool in each group.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I (INTERVENTION): Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
GROUP II (CONTROL): Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the California (CA) Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
After completion of study, patients are followed up periodically.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
California
-
Palo Alto, California, Stati Uniti, 94304
- Stanford University, School of Medicine
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- All BMT patients at Stanford who are adults and give consent
Exclusion Criteria:
- Less than 18 years of age
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Group I (Stanford Letter, interview)
Patients listen to a dialogue on the purpose of ACP.
Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT.
After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
|
Studi accessori
Receive and complete the Stanford Letter
Altri nomi:
Undergo semi-structured, research staff-led interview
|
|
Comparatore attivo: Group II (traditional advance directive, interview)
Patients listen to a dialogue on the purpose of ACP.
Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT.
After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
|
Studi accessori
Undergo semi-structured, research staff-led interview
Receive and complete the CA Advance Health Care Directive Form
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
ACP completion rate defined as a completed Advance Directive tool (either Stanford Letter or standard CA AD) brought to Stanford University for upload into the medical record
Lasso di tempo: Up to BMT day 0
|
The chi-square (X^2) test will be used to determine a significant difference in proportion of ACP tool completion and preferences for choice to prolong life between the two groups.
|
Up to BMT day 0
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Patient preferences for life sustaining measures measured via answers to the ACP questions related to use of cardiopulmonary resuscitation and use of mechanical intubation
Lasso di tempo: Up to BMT day 0
|
The X^2 test will be used to determine a significant difference in proportion of ACP tool completion and preferences for choice to prolong life between the two groups.
|
Up to BMT day 0
|
|
Uncertainty with decision making regarding end of life care measured related to the Decisional Conflict Scale (DCS) results
Lasso di tempo: Up to BMT day 0
|
Will be measured using the DCS uncertainty sub-scale (score 0-15; higher score indicates greater uncertainty).
Scores from each group will be compared by t-tests.
|
Up to BMT day 0
|
|
Understanding of the ACP tool measured using qualitative and quantitative data obtained through the semi-structured interview and DCS
Lasso di tempo: within 28 days of ACP completion
|
Will be measured using the DCS effective decision-making sub-scale (score 0-15; higher scores indicate 6 less effective decision-making).
Likert scores of understanding of the ACP from each group will be summarized and compared by t-tests.
|
within 28 days of ACP completion
|
|
Satisfaction with the ACP tool measured using qualitative and quantitative data obtained through the semi-structured interview and DCS
Lasso di tempo: within 28 days of ACP completion
|
Will be measured using the DCS effective decision-making sub-scale (score 0-15; higher scores indicate 6 less effective decision-making).
Scores from each group will be compared by t-tests.
Likert scores of satisfaction with the ACP will be summarized and compared by group using t-tests.
|
within 28 days of ACP completion
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Lori Muffly, MD, Stanford Cancer Institute
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- BMT313
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .